A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy

Blood

Volumn 104, Issue 8, 2004, Pages 2323-2331

  Engel, Christoph ^a   Scholz, Markus ^a   Loeffler, Markus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CELL HETEROGENEITY; CELL KINETICS; CHEMOSENSITIVITY; COMBINATION CHEMOTHERAPY; COMPUTER MODEL; DRUG ANALYSIS; DRUG DOSE; DRUG DOSE REGIMEN; DRUG EFFECT; GRANULOPOIESIS; LYMPHOMA; MATHEMATICAL MODEL; PRIORITY JOURNAL;

EID: 4944219924     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0306     Document Type: Article

References (57)

1. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348:2386-2395.
2. Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol. 2003;21:2466-2473.
3. Sieber M, Bredenfeld H, Josting A, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21:1734-1739.
4. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626-633.
5. Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634-641.
6. Bodey GP. Infection in cancer patients. A continuing association. Am J Med. 1986;81:11-26.
7. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
8. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325:164-170.
9. Pettengell R, Gumey H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992;80: 1430-1436.
10. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319-324.
11. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:3041-3050.
12. Tesch H, Diehl V, Lathan B, et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood. 1998;92:4560-4567.
13. Engel C, Loeffler M, Schmilz S, Tesch H, Diehl V. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol. 2000;11:1105-1114.
14. Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14:881-893.
15. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993;81:1883-1888.
16. Chatta GS, Price TH, Alien RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood. 1994;84:2923-2929.
17. Fischmeister G, Kurz M, Haas OA, et al. G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability. Ann Hematol. 1999;78:117-123.
18. Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood. 1995;86:4437-4445.
19. Hoglund M, Smedmyr B, Simonsson B, Totterman T, Bengtsson M. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant. 1996;18:19-27.
20. Houston AC, Stevens LA, Cour V. Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers. Br J Clin Pharmacol. 1999;47:279-284.
21. Huhn RD, Yurkow EJ, Tushinski R, et al. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. Exp Hematol. 1996;24:839-847.
22. Watts MJ, Addison I, Long SG, et al. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol. 1997;98:474-479.
23. Wichmann HE, Loeffler M, Schmitz S. A concept of hemopoietic regulation and its biomathematical realization. Blood Cells. 1988;14:411-429.
24. Schmitz S, Franke H, Brusis J, Wichmann HE. Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis. Exp Hematol. 1993;21:755-760.
25. Schmitz S, Franke H, Loeffler M, Wichmann HE, Diehl V. Model analysis of the contrasting effects of GM-CSF and G-CSF treatment on peripheral blood neutrophils observed in three patients with childhood-onset cyclic neutropenia. Br J Haematol. 1996;95:616-625.
26. Schmitz S, Loeffler M, Jones JB, Lange RD, Wichmann HE. Synchrony of bone marrow proliferation and maturation as the origin of cyclic haemopoiesis. Cell Tissue Kinet. 1990;23:425-442.
27. Schmitz S, Franke H, Wichmann HE, Diehl V. The effect of continuous G-CSF application in human cyclic neutropenia: a model analysis. Br J Haematol. 1995;90:41-47.
28. de Haas M, Kerst JM, van der Schoot CE, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood. 1994;84:3885-3894.
29. Layton JE, Hockman H, Sheridan WP, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood. 1989;74:1303-1307.
30. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 1992;79: 2849-2854.
31. Wintrobe MM. Wintrobe's Clinical Hematology. 7th ed. Philadelphia, PA: Lea & Febiger; 1974.
32. Wichmann HE, Loeffler M, eds. Mathematical Modeling of Cell Proliferation: Stem Cell Regulation in Hemopoiesis. Boca Raton, FL: CRC Press; 1985.
33. Loeffler M, Wichmann HE. A comprehensive mathematical model of stem cell proliferation which reproduces most of the published experimental results. Cell Tissue Kinet. 1980;13:543-561.
34. Scheding S, Franke H, Diehl V, et al. How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation? Results of a computer simulation. Exp Hematol. 1999;27:956-965.
35. Scheding S, Loeffler M, Anselstetter V, Wichmann HE. A mathematical approach to benzo[a]pyrene-induced hematotoxicity. Arch Toxicol. 1992;66: 546-550.
36. Dale DC, Fauci AS, Wolff SM. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med. 1974;291:1154-1158.
37. Gorschluter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol. 1995;6:477-482.
38. Schwefel HP. Evolution strategies: a family of nonlinear optimization techniques based on imitating some principles of organic evolution. Ann Oper Res. 1984;1:S65-S167.
39. Rechenberg I. The evolution strategy: a mathematical model of Darwinian evolution. In: Frehland E, ed. Springer Series in Synergetics 22. Berlin, Germany: Springer; 1984:122-132.
40. Ostby I, Rusten LS, Kvalheim G, Grottum P. A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation. J Math Biol. 2003; 47:101-136.
41. Morstyn G, Nicola NA, Metcalf D. Separate actions of different colony stimulating factors from human placental conditioned medium on human hemopoietic progenitor cell survival and proliferation. J Cell Physiol. 1981;109:133-142.
42. Begley CG, Nicola NA, Metcalf D. Proliferation of normal human promyelocytes and myelocytes after a single pulse stimulation by purified GM-CSF or G-CSF. Blood. 1988;71:640-645.
43. Lord BI, Bronchud MH, Owens S, et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A. 1989;86:9499-9503.
44. Engel C. Characterization of the cell kinetic effects of G-CSF on granulopoiesis, erythropoiesis and hematopoietic stem cells in the mouse using a mathematical compartment model [thesis]. University of Cologne, Cologne, Germany: 1999.
45. Mackey MC, Aprikyan AA, Dale DC. The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans. Cell Prolif. 2003;36:27-34.
46. Sturgill MG, Huhn RD, Drachtman RA, Ettinger AG, Ettinger LJ. Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelo-suppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing. Am J Hematol. 1997;54: 124-130.
47. Watari K, Ozawa K, Takahashi S, et al. Pharmacokinetic studies of intravenous glycosylated recombinant human granulocyte colony-stimulating factor in various hematological disorders: inverse correlation between the half-life and bone marrow myeloid cell pool. Int J Hematol. 1997;66:57-67.
48. Borleffs JC, Bosschaert M, Vrehen HM, et al. Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects. Clin Ther. 1998;20:722-736.
49. Benson AB III, Read TR, Goebel SL, Koeller JM, Tormey DC. Correlations between leukocyte count and absolute granulocyte count in patients receiving cancer chemotherapy. Cancer. 1985; 56:1350-1355.
50. Brigden ML, Mawji KB, Wilson KS, Spinelli JJ. The relationship between the absolute granulocyte count, platelet count and total leukocyte count in cancer chemotherapy patients. Clin Invest Med. 1991;14:395-401.
51. Li FP, Danahy J, Gelman R. Utility of differential leukocyte counts in cancer management. JAMA. 1984;252:1312-1314.
52. Lohrmann HP, Schreml W. Cytotoxic drugs and the granulopoietic system. Recent Results Cancer Res. 1982;81:1-222.
53. Chatta GS, Andrews RG, Rodger E, Schrag M, Hammond WP, Dale DC. Hematopoietic progenitors and aging: alterations in granulocytic precursors and responsiveness to recombinant human G-CSF, GM-CSF, and IL-3. J Gerontol. 1993;48: M207-M212.
54. Chatta GS, Dale DC. Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. Drugs Aging. 1996;9:37-47.
55. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 1996;88:335-340.
56. Hasenclever D, Brosteanu O, Gerike T, Loeffler M. Modelling of chemotherapy: the effective dose approach. Ann Hematol. 2001;80(suppl 3):B89-B94.
57. Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol. 1996;7(suppl 4):95-98.